Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.
about
Suppression of the Arboviruses Dengue and Chikungunya Using a Dual-Acting Group-I Intron Coupled with Conditional Expression of the Bax C-Terminal DomainGene Therapy for Pediatric Cancer: State of the Art and Future PerspectivesGroup I aptazymes as genetic regulatory switches.Emerging clinical applications of RNAPrognostic significance of multidrug-resistance protein (MDR-1) in renal clear cell carcinomas: a five year follow-up analysis.Targeting of highly conserved Dengue virus sequences with anti-Dengue virus trans-splicing group I introns.Effective suppression of dengue virus using a novel group-I intron that induces apoptotic cell death upon infection through conditional expression of the Bax C-terminal domainAdvances in gene therapy for malignant melanoma.Efficient and specific repair of sickle beta-globin RNA by trans-splicing ribozymes.5' exon replacement and repair by spliceosome-mediated RNA trans-splicingImaging Tetrahymena ribozyme splicing activity in single live mammalian cells.Cancer chemoresistance: the relationship between p53 and multidrug transporters.Defects in G1-S cell cycle control in head and neck cancer: a review.Trans-splicing repair of mutant p53 suppresses the growth of hepatocellular carcinoma cells in vitro and in vivo.Targeted genetic repair: an emerging approach to genetic therapy.Ribozyme-mediated revision of RNA and DNAMessenger RNA reprogramming by spliceosome-mediated RNA trans-splicingSpliceozymes: ribozymes that remove introns from pre-mRNAs in trans.Engineered ribozymes as molecular tools for site-specific alteration of RNA sequence.Novel cancer therapy by reactivation of the p53 apoptosis pathway.Computational prediction of efficient splice sites for trans-splicing ribozymes.The molecular underpinnings of genetic phenomena.[The use of p53 as a tool for human cancer therapy].Molecular approaches to sarcoma therapy.Low selection pressure aids the evolution of cooperative ribozyme mutations in cellsThe structure and function of catalytic RNAs.Irinotecan therapy and molecular targets in colorectal cancer: a systemic review.Transcriptional repression by p53 through direct binding to a novel DNA element.Molecular recognition properties of IGS-mediated reactions catalyzed by a Pneumocystis carinii group I intron.Specific and Efficient Regression of Cancers Harboring KRAS Mutation by Targeted RNA Replacement.Selections for constituting new RNA-protein interactions in catalytic RNP.Functional repair of a mutant chloride channel using a trans-splicing ribozymeNuclear group I introns in self-splicing and beyond.Selective and efficient retardation of cancers expressing cytoskeleton-associated protein 2 by targeted RNA replacement.Exploiting differential RNA splicing patterns: a potential new group of therapeutic targets in cancer.Detection of mRNA in mammalian cells with a split ribozyme reporter.Achilles' heel of cancer?
P2860
Q24701733-D31E7274-BD12-4E35-9055-CE813D6D013FQ24792778-29439096-492E-4EDC-A379-A268B5AF50DFQ24794819-85D3409D-15D6-46E1-AA4F-137A9E04BE11Q28214164-1B62ED4E-DF4C-47FD-9711-E858D7672338Q33267032-F91FBDCA-28D3-4295-9C76-5A493A2AB535Q33747091-458C88EC-1595-474F-8F28-71C6AC0F1B77Q33923881-E7AF5467-670B-41EC-92BB-04BDEBCC77E8Q34119859-B75C02D0-B65E-40BB-A8EA-02D068AA3350Q34365376-7F7A71FA-B4B2-4741-B08E-F5CF21804289Q34365389-D01A0D88-91D4-4AF2-983E-AB7C17FF59EEQ34387772-B1E36BA2-A974-421B-AF3E-BE17F2DF0176Q34580489-85F7DA5A-B894-440E-BB9D-94A04AEA5E92Q34733424-0E5503F2-2F83-4F28-B451-A8C4ABD0B813Q35138721-4FC1856C-DE44-4A87-AAE5-EC99AD98FC40Q35190980-ABB5369C-6828-4581-926C-43488167C4C6Q35190983-B6654E17-0CC1-4431-BE50-7188D5064446Q35202462-7C751B36-937F-4F74-B1A5-EAE886B0F175Q35205340-97E67778-FAE2-47F9-8056-120B4EDD8AF8Q35549357-DB88ADD8-D7DD-456C-A44B-B67E8C5604F8Q35597613-54759502-7A4C-46DE-B633-85EC37946321Q35775827-1C435FA7-0F49-43DC-8EDF-D82A48464BE8Q36921977-07694DE5-2265-433E-BBED-CB542C673129Q37081504-96C85793-0DB0-44ED-A44C-AD154C4C6FC7Q37180948-501E37EB-32CC-4771-9495-CB9F2D8A6297Q37311367-5CBF48C5-284D-4088-927E-E6A2CF9C4C17Q37417135-E7030F83-1593-4F42-A6F3-E3085E8EB1BAQ37571729-AA473371-8AAD-43E8-8E7D-03EA65EDB714Q38300895-7F970481-6E91-47A3-87B6-24511C43C048Q38356388-93E8CC6A-A9E1-4196-984C-AE0929A2D993Q38718304-4F3CF156-75A3-47FA-8FD3-2C9D018CEB64Q39698001-1C1BB600-AF40-47F9-AFDC-B1681E2A974AQ39740174-CBB848AE-2CA2-4EEE-9588-73380927443CQ42036073-B0715372-611C-4FB8-9361-4916FFDFC67FQ45867347-AD82C16A-2615-4CE2-9367-1E39538A60A9Q47784889-4F0816FD-7597-48A6-B5F6-ED7BED5B6891Q54604030-8D16718B-24C9-45DB-A628-A266D7A1F4ADQ59091650-410D7C62-86F0-45BF-ABCD-2D731FAF7C69
P2860
Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on July 2000
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@en
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@nl
type
label
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@en
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@nl
prefLabel
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@en
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@nl
P2860
P356
P1476
Induction of wild-type p53 act ...... repair mutant p53 transcripts.
@en
P2093
B A Sullenger
T Watanabe
P2860
P304
P356
10.1073/PNAS.150104097
P407
P577
2000-07-01T00:00:00Z